Physician profile
Deepak Kapoor
NPI 1457308926
$3,253.04
in general payments reported to CMS, 2019-2025
20 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $220 · 2021: $18.00 · 2022: $14.78 · 2023: $106 · 2024: $901 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.78 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $433.01 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $402.63 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $380.51 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $332.70 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $325.24 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $307.13 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $302.37 | 2019-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $225.56 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $125.56 | 2019-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $97.09 | 2024-2025 | Auvelity |
| Abbvie INC. | $74.88 | 2024-2025 | |
| Allergan, INC. | $56.58 | 2019 | |
| Supernus Pharmaceuticals, INC. | $49.55 | 2025 | Qelbree |
| Bausch Health US, LLC | $29.54 | 2019 | |
| Indivior INC. | $23.30 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.10 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $18.01 | 2024 | Trintellix |
| Pacira Therapeutics, INC. | $18.00 | 2021 | |
| Noven Therapeutics, LLC | $16.71 | 2024 | Secuado |
| Owp Pharmaceuticals, INC. | $16.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.